Recent studies showed that GP73 was over-expressed in several cancers, such as hepatocellular carcinomas [9-11], bile duct carcinomas [11], lung adenocarcinomas [12], prostate cancer [13,14] and seminomas [15]. This evidence concerns the gene GOLM1 and prostate cancer.